Xtant Medical Holdings Inc. (AMEX:XTNT) saw a downside of -0.42% to $1.18 after subtracting -$0.01on Wednesday. The 5-day average trading volume is 158,161 shares of the company’s common stock. It has gained $1.2380 in the past week and touched a new high 3 times within the past 5 days. An average of 203,375 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 129,610.
XTNT’s 1-month performance is 37.63% or $0.3096 on its low of $0.8311 reached on 07/26/23. The company’s shares have touched a 52-week low of $0.46 and high of $1.38, with the stock’s rally to the 52-week high happening on 08/09/23. YTD, XTNT has achieved 79.55% or $0.5296 and has reached a new high 19 times. However, the current price is down -14.13% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
XTNT stock investors last saw insider trading activity on Jan 18.Neils Scott C (Chief Financial Officer) most recently sold 8,673 shares at $0.61 per share on Jan 18. This transaction cost the insider $5,283. President and CEO, Browne Sean E, sold 51,100 shares at a price of $0.62 on Oct 19. Then, on Oct 18, President and CEO Browne Sean E sold 80,000 shares at a price of $0.68 per share. This transaction amounted to $54,008.
Valuation Metrics
XTNT stock has a beta of 0.70. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 2.21 while the price-to-book (PB) in the most recent quarter is 4.23.
Xtant Medical Holdings Inc.’s quick ratio for the period ended June 29 was 1.10, with the current ratio over the same period at 2.30. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.54, while the total debt to equity was 0.72. In terms of profitability, the gross margin trailing 12 months is 57.70%. The trailing 12-month EBITDA margin is -9.42% while for the period ending June 29, Xtant Medical Holdings Inc.’s operating margin was -9.70%. The firm’s gross profit as reported stood at $32.14 million against revenue of $57.97 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 21.92% to -$2.19 million, while revenue of -$2.08 million was 5.02% off the previous quarter. Analysts expected XTNT to announce -$0.02 per share in earnings in its latest quarter, but it posted -$0.02, representing a 0.00% surprise. EBITDA for the quarter stood at more than -$0.59 million. XTNT stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 34.26 million, with total debt at $23.56 million. Shareholders hold equity totaling $128.9 million.
Let’s look briefly at Xtant Medical Holdings Inc. (XTNT) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 August was 61.50% to suggest the stock is trending Neutral, with historical volatility in this time period at 31.58%.
The stock’s 5-day moving average is $1.1819, reflecting a +5.27% or $0.0596 change from its current price. XTNT is currently trading +32.77% above its 20-day SMA, +91.87% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +77.55% and SMA200 by+84.43%.
Stochastic %K and %D was 47.61% and 49.46% and the average true range (ATR) pointed at 0.0898. The RSI (14) points at 62.14%, while the 14-day stochastic is at 45.60% with the period’s ATR at 0.0914. The stock’s 9-day MACD Oscillator is pointing at 0.0121 and 0.0192 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Xtant Medical Holdings Inc. (AMEX: XTNT), Maxim Group reiterated its a Buy rating for the company but lifted their price target by $10 to $6. Analysts offering their rating for XTNT stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate XTNT as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.
What is XTNT’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $1.35 and a high of $1.35, with their median price target at $1.35. Looking at these predictions, the average price target given by analysts is for Xtant Medical Holdings Inc. (XTNT) stock is $1.35.
